Filing summary
Business context and reporting period
Important identity discrepancy: The supplied filing is for Trail One, Inc., not Citius Pharmaceuticals, Inc. It is a Form 10-Q for the quarter ended December 31, 2012 (Trail One’s first fiscal quarter of 2013), and was signed February 8, 2013.
Trail One is a development-stage company developing and marketing customized automobile license plate tags as accessories. It reported no sales or revenue to date and had not commenced major operations.
Financial results and position
- Quarter revenue was $0, unchanged from the prior-year quarter.
- Operating expenses were $636 versus $2,196; interest expense was $784 versus $372. Net loss was $1,420 versus $2,568, an improvement of $1,148 (about 45%). No income-tax provision was recorded.
- Cash used in operating activities was $236; financing provided $200; cash declined by $36 to $99. No investing cash flows were reported.
- At December 31, 2012, total assets were $99, current liabilities were $47,366, and working capital and stockholders’ equity were each negative $47,267. Accumulated deficit was $65,267.
- Notes payable totaled $38,940 principal: $21,693 owed to the CEO and $17,247 to a non-related party. Both bear 8% interest and are due on demand. Accrued interest totaled $3,876. The filing provides no revenue or gross-margin basis for assessing margins.
Changes, outlook, and risks
Compared with the prior-year quarter, lower operating expenses more than offset higher interest expense, reducing the net loss. The company said it needed additional funding to build its website and complete marketing plans; it estimated a $75,000 capital need and a monthly burn rate of about $1,630. It planned to begin sales to the public and anticipated an online purchasing site in September 2013, but said it did not expect revenue to cover expenses for at least the next 12 months.
Management disclosed substantial doubt about the company’s ability to continue as a going concern. Cash was insufficient for planned operations, and continued operations depended on obtaining financing with no assurance it would be available or acceptable. Management also cited potential dilution from equity issuance and operating restrictions or senior claims from debt. Subsequent to quarter-end, BK Consulting advanced three unsecured, 8% demand loans totaling $6,173 (January 4, 15, and 30, 2013).
Disclosure controls and procedures were deemed ineffective. The filing cited no independent board or audit committee, inadequate segregation of duties, and reliance on a financial consultant for financial reporting. The company reported no material pending legal proceedings and no material changes to its previously disclosed risk factors.
Investor verification priorities
- Confirm the filing belongs to Trail One, Inc.; it does not match the Citius Pharmaceuticals, Inc. company metadata.
- Reconcile cash-flow disclosures: the cash-flow statement reports quarterly operating cash use of $236 and inception-to-date use of $56,841, while MD&A separately states inception-to-date use of $58,841.
- Verify the company’s near-term funding needs, availability and terms of financing, and the status of the proposed website and product launch.
- Review the demand-note balances, accrued interest, and post-quarter-end advances, along with the disclosed going-concern uncertainty and ineffective controls.